ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $327,740 | -8.2% | 3,500 | -12.5% | 0.00% | -100.0% |
| Q2 2023 | $357,000 | -84.7% | 4,000 | -81.7% | 0.00% | -80.0% |
| Q1 2023 | $2,337,396 | +18.9% | 21,800 | +35.4% | 0.01% | -16.7% |
| Q4 2022 | $1,966,293 | +495.8% | 16,100 | +403.1% | 0.01% | +500.0% |
| Q3 2022 | $330,000 | -9.1% | 3,200 | -17.9% | 0.00% | 0.0% |
| Q2 2022 | $363,000 | -74.2% | 3,900 | -67.5% | 0.00% | -80.0% |
| Q1 2022 | $1,408,000 | +110.5% | 12,000 | +185.7% | 0.01% | +66.7% |
| Q3 2021 | $669,000 | +58.9% | 4,200 | +31.2% | 0.00% | +50.0% |
| Q2 2021 | $421,000 | -16.3% | 3,200 | -17.9% | 0.00% | 0.0% |
| Q1 2021 | $503,000 | +11.8% | 3,900 | +44.4% | 0.00% | 0.0% |
| Q4 2020 | $450,000 | – | 2,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |